Cantor Fitzgerald raised the firm’s price target on Bristol Myers (BMY) to $54 from $45 and keeps a Neutral rating on the shares. The firm does not expect the Q1 earnings season to “dramatically reinvigorate” the large-cap pharma sector. Cantor says Bristol’s second half of 2026 catalysts around admilparant, milvexian and Cobenfy matter more than a “primarily legacy-driven beat” in Q1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks
- Trump administration readying new pharmaceutical tariffs, FT reports